[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gi-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gi-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,71,99,133,165,199,224,243,272],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641950","gustabor-phase-2---treating-taste-changes-during-cancer-therapy-a-randomized-study-evaluating-an-ai--based-nutrition-intervention-100641950",false,"NCT07649681","Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention","GustaborRCT","Inclusion Criteria:\n\n* Age ≥ 18\n* Suffering from one of the following tumor entities: Multiple myeloma, melanoma, urogenital cancer or malignant tumor of the gastrointestinal tract\n* Mainly oral nutrition\n* Subjectively perceived tumor therapy-related taste disorder\n* At least two clinical presentations planned within 12 weeks with a minimum interval of three weeks\n* Ability to participate in nutritional intervention, including use of the online portal and implementation of recipe suggestions (e.g. resources and access to a kitchen), either independently or with third-party support (e.g. by relatives, outpatient care services).\n\nExclusion Criteria:\n\n* Pregnancy\n* Taste disorder explained by other causes (e.g. existing before therapy or COVID disease)\n* Placement in an inpatient care facility","ALL","18 Years",{"count":19,"type":20},198,"ESTIMATED","INTERVENTIONAL",[23],"NA","The study investigates taste disorders that commonly occur during or after cancer treatment, often leading to issues such as malnutrition and treatment discontinuation. Although many non-pharmacological recommendations exist, it is unclear which methods are suitable for which individuals.\n\nThis randomized study aims to compare the effectiveness of individualized dietary recommendations (Gustabor group) with the current standard of care -general recommendations (Control group). Participants will undergo an objective assessment of taste disorders using taste strips and questionnaires. Based on the results, the Gustabor group will receive both general and specific dietary suggestions. These will be accomapnied by AI-generated recipe suggestions tailored to specific taste disorders (e.g., more cold foods in cases of metallic taste). The control group will receive the current standard: a flyer containing general dietary advice for oncology patients previously shown to be beneficial for managing taste alterations. The primary endpoint is the PG-SGA score within 12 weeks of inclusion.",[26,27,28,29,30],"Multiple Myeloma (MM)","GI Cancer","Taste Disorder","Melanoma (Skin Cancer)","Urogenital Cancers","NOT_YET_RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":20},"2026-07-01",{"date":39,"type":20},"2026-12-31",{"name":41,"class":42},"Wuerzburg University Hospital","OTHER",6,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100642375","gutcheck-optimization-of-a-personalized-mobile-health-app-for-survivors-of-gastrointestinal-cancer-100642375","NCT07661017","GutCheck: Optimization of a Personalized Mobile Health App for Survivors of Gastrointestinal Cancer","Inclusion\n\nSurvivors of GI cancer are eligible if they are:\n\n* ≥18 years old\n* reside in or have received cancer care in Minnesota\n* own a smartphone • consent to install the GutCheck app and discontinue diet tracking in other lifestyle apps (e.g., MyFitness, Fitbit, Noom).\n* are English-speaking\n* have received a GI cancer diagnosis (e.g., esophageal, gastric, colorectal, liver, pancreatic, etc)\n* At least 2 months post-cancer treatment\n\nInclusion criteria for oncology specialists (oncologists, advanced practice providers, nurses, dietitians, and patient navigators) include:\n\n* Have interacted with at least 1 cancer patient or survivor in the past month.\n* Have experience working with electronic health records (EHR).\n\nExclusion\n\n* Currently pregnant (Patient Study ONLY)\n* Pregnancy status may be self-reported by the participant.\n* Individuals who are postmenopausal, surgically sterile, or otherwise unable to become pregnant are not subject to this exclusion.\n* Active cancer or receiving treatment for another cancer.\n* Currently taking or has taken antibiotics in the last 3 months.\n* Diagnosis of inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), and\u002For celiac disease.\n* Involuntary weight loss of 10% or more of usual body weight within 6 months, or involuntary loss of 5% or more of usual body weight in 1 month.\n\nOncology specialists' exclusion criteria include:\n\n* Unable to participate in an interview",true,{"count":52,"type":20},200,[23],"There are two components to the study: a patient and a clinician study. The clinician study will include one-hour semi-structured interviews with oncology specialists to identify facilitators and barriers to integrating digital diet interventions into the clinical workflow, and to understand their needs and preferences for digital diet interventions. The patient study aims to investigate initial feasibility, efficacy and acceptability of the GutCheck app and intervention. It will last 9 weeks and involves 2 study visits and 2 active phases with a transition week and optional transition visit between phases. During active phases, participants will be asked to use the GutCheck app every day. Prior to the first active phase, participants will go through informed consent and app training. The first active phase will last two weeks and will focus on tracking participants' diet, gastrointestinal (GI) symptoms, and stress. The data collected during the first active phase will be used to identify any potential trigger foods that may contribute to GI symptoms, but only if the participant reports experiencing GI symptoms. Between active phases, participants will have one Transition Week, where results from the first phase are given to the participants with the option to attend a Transition Week Visit. The second active phase will last four weeks and will involve the message intervention. A single-blind, micro-randomized trial design will be used to repeatedly randomize participants to different intervention combinations, determining both the timing and frequency of intervention message delivery throughout the day. Lastly, there will be an exit visit and interview within a week from the intervention to collect post-intervention measures and ask about the participant's experience with the GutCheck app.",[56,57,58,59,60,61,27],"Gastrointestinal","Mobile Health","Gastrointestinal Symptoms","Gut Health","Gastrointestinal Cancer","Survivorship","2026-06-16",{"date":64,"type":35},"2026-06-22",{"date":66,"type":20},"2026-12",{"date":68,"type":20},"2030-06",{"name":70,"class":42},"Masonic Cancer Center, University of Minnesota",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":5},"100637149","the-canopy-cancer-collective-clinical-registry-protocol-100637149","NCT07605702","The Canopy Cancer Collective Clinical Registry Protocol","Inclusion Criteria:\n\nRetrospective Cohort:\n\n1. Must have reached the age of majority in the jurisdiction where enrolled (18 years; Alabama\u002FNebraska 19; Puerto Rico 21).\n2. Must have histologically proven GI cancer seen at the site within the 20 years preceding activation, and are:\n\n   1. Deceased, or\n   2. Lost to follow-up ( \\>1 year lapse in contact since last visit).\n\nProspective Cohort:\n\n1. Must have reached the age of majority in the jurisdiction where enrolled (18 years; Alabama\u002FNebraska 19; Puerto Rico 21).\n2. Must have histologically proven Gastrointestinal (GI) cancer.\n3. Patient or legally authorized representative capable of understanding and willing to provide signed informed consent (assent if applicable).\n4. Patient\u002FLegally Authorized Representative (LAR) agrees to collection of clinical data and information available on archival tissue and subsequent excess specimens obtained as part of standard-of-care.\n\nExclusion Criteria:\n\nRetrospective Cohort:\n\n1\\. Cases in which patient's medical chart denotes restricted use of health information.\n\nProspective Cohort:\n\n1\\. Prisoners will not be approached for participation.",{"count":78,"type":20},100000,"2 Years","OBSERVATIONAL","The Canopy Cancer Collective Clinical Registry Protocol Non-Interventional Data and Sample Collection Registry Protocol\n\nNumber of study sites 15 Study Design - Observational, registry Primary Objective To systematically collect and store comprehensive data on gastrointestinal cancer patients, encompassing both their past medical history and future clinical experiences, to address specific future research questions related to these malignancies, to establish and share best practices, and to support quality improvement initiatives focused on enhancing patient care and outcomes.\n\nSecondary Objective(s) 1. Leverage the collective to increase access to molecular profile and biomarker (ctDNA) matched clinical trials across the treatment trajectory.\n\n2\\. Use real world data and patient reported outcomes to improve patient care throughout the treatment trajectory.\n\nResearch Procedure(s) Collection of clinical and outcome data and cataloging and facilitating access to physical biological specimens and their associated data for future research purposes.\n\nDrugs\u002FDevices used on Study None Study Population Patients with diagnosis of gastrointestinal (GI) cancers who seek care at one of the canopy centers and\u002For their affiliates Sample Size Up to 30000 patients in the prospective component\n\nUp to 70000 subjects will be enrolled on the retrospective component Study Duration for Individual Participants Anticipated to be at least 1 year Study Specific Abbreviations AE: Adverse Event CEC: Clinical Events Committee CT: Computed Tomography iCCA: Intrahepatic cholangiocarcinoma MRI: Magnetic Resonance Imaging OS: Overall Survival PFS: Progression Free Survival",[83,84,85,86,87,88,27],"Gastrointestinal Neoplasms","Pancreatic Cancer","Colorectal Cancer","GI Cancers","PDAC - Pancreatic Ductal Adenocarcinoma","PDAC","2026-05-18",{"date":91,"type":35},"2026-05-26",{"date":93,"type":20},"2026-05",{"date":95,"type":20},"2038-05",{"name":97,"class":98},"Canopy Cancer Collective, LLC","NETWORK",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":117,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100463322","prospective-evaluation-of-pencil-beam-scanning-proton-therapy-for-previously-irradiated-tumors-100463322","NCT05313191","Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors","ReRT","Inclusion Criteria:\n\n* Age 18 years\n* Patient provides study specific informed consent prior to study entry.\n* Documented history and physical exam within 90 days prior to registration.\n* ECOG PS 0, 1, or 2 within 90 days prior to registration\n\nExclusion Criteria:\n\n* Non malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.\n* Prior invasive non study malignancy unless disease free for ≥ 3 years\n\n  * Non melanoma skin cancer, low risk prostate cancer, well differentiated thyroid cancers, in situ carcinomas of the oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the patient are permissible.\n* History of active connective tissue disorder (i.e., systemic lupus erythematosus, scleroderma), dermatomyositis, xeroderma pigmentosum",{"count":107,"type":20},1800,[23],"The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional photon (or x-ray) radiation therapy, which uses high-energy waves to kill tumor cells. In some cases, the cancer either returns or a new tumor can present in a different part of the body. With the usual radiation treatment, the photon beams travel all the way through the body. As a result, healthy tissues in front of and behind the tumor are exposed to radiation. Physicians who treat these cases where the tumor has returned often use a much lower dose of radiation to prevent patients from experiencing serious and long-term side-effects. This dose is often not strong enough to destroy the cancerous tumor. Alternatively, they may also treat a smaller area than would be indicated for complete tumor eradication, again in an attempt to prevent serious and long-term toxicities, but at the cost of optimally treating the cancer. Proton therapy, however, may offer a chance to safely deliver a more effective dose and volume of radiation as it is more targeted and can spare healthy tissues surrounding the tumor.\n\nThe reason we are conducting this research study is to look at whether Proton therapy can be a better way to treat reoccurring tumors in patients who have previously received radiation therapy to the same area, compared to treatment approaches used to date.",[111,112,27,113,114,115,116],"CNS Cancer","Head and Neck Cancer","Gynecologic Cancer","Prostate Cancer","Thoracic Cancer","Breast Cancer",[118,119,120,121],"Reirradiation","Cancer","Proton Therapy","Radiation Therapy","RECRUITING","2026-04-06",{"date":125,"type":35},"2026-04-13",{"date":127,"type":35},"2022-01-24",{"date":129,"type":20},"2028-01",{"name":131,"class":42},"The New York Proton Center",1,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":143,"conditions":144,"keywords":152,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":43},"100450172","avera-cancer-sequencing-and-analytics-protocol-asap-100450172","NCT05142033","Avera Cancer Sequencing and Analytics Protocol (ASAP)","Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)","ASAP","Inclusion Criteria:\n\n* Must be at least 18 years of age\n* Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer\n* Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation\n\nExclusion Criteria:\n\n* Participants incapable of understanding the items listed in the consent form and process\n* Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements",{"count":142,"type":20},25000,"The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim to identify the underlying genomic drivers of premalignant and malignant conditions across a range of disease stages and cancer types.\n\nComprehensive molecular profiling will include somatic tumor testing (tissue and\u002For blood) using next-generation sequencing. Selected subsets of samples may undergo whole exome and\u002For whole transcriptome sequencing for research purposes. Pharmacogenomic testing will also be performed to better understand individual variability in medication response and to identify opportunities for optimizing treatment. In addition, participants may optionally provide microbiome samples.\n\nTo maximize the value of the genomic data, participants who consent to this protocol will have their electronic health records-both retrospective and prospective-abstracted, curated, annotated, and linked to the genomic data generated through study testing. Given the long-term value of these data, participants may also voluntarily consent to the storage of their biological samples in a biobank and to the use of their de-identified information for future research.\n\nData collected from this participant population will support efforts to advance the understanding of cancer biology, as well as the discovery and validation of biomarkers associated with clinical outcomes. Findings may also be shared through collaborative research initiatives to further promote advancements in cancer research.",[119,145,146,116,147,148,27,113,149,150,111,151],"Cancer Diagnosis","Early Detection of Cancer","Lung Cancer","Colon Cancer","Ovarian Cancer","Endometrial Cancer","Hematologic Cancer",[119,153,154,155,156],"Genomics","Genetics","Microbiome","Pharmacogenomics","2026-03-23",{"date":159,"type":35},"2026-03-27",{"date":161,"type":35},"2021-11-01",{"date":39,"type":20},{"name":164,"class":42},"Avera McKennan Hospital & University Health Center",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":198},"100597096","improving-diagnosis-and-treatment-for-patients-with-rectal-cancer-100597096","NCT07054047","Improving Diagnosis and Treatment for Patients With Rectal Cancer","Improving the Prognostic Accuracy of Staging Rectal Cancer Using Magnetic Resonance Imaging (MRI) - Detected Tumour Deposits and Vascular Invasion (mrTDV) Instead of Tumour Nodal Metastasis (mrTNM)","MERCURY 3","Inclusion Criteria:\n\n1. Have a rectal cancer proven on biopsy or subsequent surgery\n2. Sites able to submit anonymised MRI staging scans, pathology and imaging reports for central review\n3. Aged 16 years or over\n\nExclusion Criteria:\n\n1. Have irresectable metastatic disease at time of initial staging\n2. Undergoing palliative treatment for Rectal Cancer\n3. Have a biopsy-proven rectal malignancy which is not adenocarcinoma\n4. Are contraindicated for MRI staging","16 Years","99 Years",{"count":176,"type":20},438,[23],"The cancer stage information from scans guides pre-operative treatment and the type of surgery offered. The investigators are studying whether a new Magnetic Resonance Imaging (MRI) staging method can improve the accuracy of prognosis for patients diagnosed with rectal cancer. The investigators will provide consultant radiologists with the know-how to report MRI scans using this new method and compare this with the existing method. This study will test this by comparing how accurately the old versus new method predict the outcomes of patients. The existing method relies on radiologists determining if tumour has spread through the bowel wall or not and whether there are suspected malignant lymph nodes. The new method looks for tumour spread into the veins and whether or not there are tumour deposits. Our previous research has shown that the new method is much more accurate at predicting prognosis, but this finding needs to be verified by a larger multicentre study.\n\nThe investigators are also studying the patient journey, so the investigators can better understand patients' experiences and the impact that treatments have on their quality of life. The investigators wish to understand if improvements in the accuracy of prognosis from scans could change treatment decisions in future. The investigators will also compare the radiology scan prediction of prognostic factors by looking carefully at the tumour specimens.",[27],[181,182,183,184,185,186,187,188],"Shared decision making","Radiotherapy","Quality of Life","MRI Staging","MDT Decision Making","Histopathological Staging","Rectal Cancer","Preoperative staging","2025-06-26",{"date":191,"type":35},"2025-07-08",{"date":193,"type":20},"2025-07-01",{"date":195,"type":20},"2031-05-31",{"name":197,"class":42},"Imperial College London",3,{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":198},"100596033","gustabor-phase-1---ai-based-creation-of-a-nutritional-plan-to-compensate-for-chemotherapy-induced-taste-disorders-100596033","NCT07040189","Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders","GustaborPilot","Inclusion Criteria:\n\n* Age ≥ 18\n* Suffering from one of the following tumor entities: Multiple myeloma or malignant tumor of the gastrointestinal tract\n* Mainly oral nutrition\n* Subjectively perceived tumor therapy-related taste disorder\n* At least two clinical presentations planned within 12 weeks with a minimum interval of three weeks\n* Ability to participate in nutritional intervention, including use of the online portal and implementation of recipe suggestions (e.g. resources and access to a kitchen), either independently or with third-party support (e.g. by relatives, outpatient care services).\n\nExclusion Criteria:\n\n* Pregnancy\n* Taste disorder explained by other causes (e.g. existing before therapy or COVID disease)\n* Placement in an inpatient care facility",{"count":207,"type":20},51,[23],"The study investigates taste disorders that commonly occur during or after cancer treatment, often leading to issues such as malnutrition and treatment discontinuation. Although many non-pharmacological recommendations exist, it is unclear which methods are suitable for which individuals. This pilot study aims to use an AI-based, or rule-driven system to generate personalized recommendations based on patients' specific impairments and taste disorder. For the pilot study, the AI will be trained on recipes to create individualized meal plans, helping to identify foods that are likely to be better. The primary endpoint is the assessment of the nutritional intervention as helpful at the second visit within 12 weeks of inclusion.",[211,27,212],"Multiple Myeloma","Taste Disorders",[214,215],"taste disorders","AI","2025-06-17",{"date":218,"type":35},"2025-06-27",{"date":220,"type":20},"2025-08-01",{"date":222,"type":20},"2025-12-31",{"name":41,"class":42},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":241,"locationsCount":4},"100587494","prevalence-of-types-and-patterns-of-gastrointestinal-polyps-in-assiut-university-hospitals--cross-sectional-study-100587494","NCT06929117","Prevalence of Types and Patterns of Gastrointestinal Polyps in Assiut University Hospitals ( Cross Sectional Study","Polyp","Inclusion Criteria:All patients diagnosed with Gastrointestinal polyp based on standard clinical, endoscopic, and histological criteria will be included in the study.\n\n\\-\n\nExclusion Criteria:\n\n* Patients with insufficient data were excluded",{"count":232,"type":20},130,"Gastrointestinal polyps (GIPs) are unusual growths of epithelial tissue projecting from the mucosa of gastrointestinal tract (GIT) and one of the most common pathologies affecting GIT . They are either proliferative or neoplastic mucosal lesions that are commonly seen in the colon and less commonly occur in the esophagus, stomach and small intestine. They may remain asymptomatic or present as bleeding, pain and obstruction due to mass effect. However, the most important risk with the gastrointestinal polyps is the development of malignancy in some of these polyps . Gastric polyps include hyperplastic, fundic gland polyps, inflammatory fibroid polyp, adenomas like pyloric gland adenoma, and oxyntic gland adenoma. Hyperplastic gastric polyps rarely undergo neoplastic progression (1.5-2.1%) but are associated with an increased risk of synchronous cancer occurring elsewhere in the gastric mucosa . Gastric adenomas are true neoplasms and precursors of gastric cancer. Adenomas larger than 20 mm in width and villous histology have a higher risk of neoplastic progression . The presence of gastric adenomas is strongly associated with synchronous or metachronous gastric adenocarcinoma . Polyps of the small bowel are rare compared to those of the colo-rectum, with adenomas being most common and having more preference for the distal duodenum, ampullary, and periampullary region Colonic Polyps may be classified according to their gross appearance (sessile or pedunculated), histopathological features (hyperplastic, adenoma, etc.), and behavior (benign or malignant). The biggest concern is their ability to progress into adenocarcinoma, through the adenoma to carcinoma sequence due to genetic mutation .",[27],"2025-04-14",{"date":237,"type":35},"2025-04-16",{"date":239,"type":20},"2025-09",{"date":66,"type":20},{"name":242,"class":42},"Assiut University",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":252,"studyType":80,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":132},"100501059","the-australia-and-new-zealand-multicentre-upper-gastrointestinal-endoscopic-tissue-resection-study-100501059","NCT05804331","The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study","ANZ UGI","Inclusion Criteria:\n\n* UGI neoplastic lesions \\> 10mm\n\n  * Lesions for ESD limited to the mucosal and\u002For submucosal layer OR\n  * Lesions for EFTR limited to the muscularis propria layer OR\n  * Lesions for STER limited to the submucosal and\u002For muscularis propria layer\n* Aged 18 years or older\n\nExclusion Criteria:\n\n* Age less than 18\n* Unable to give informed consent\n* Pregnant or lactating patients\n* Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally",{"count":251,"type":20},500,"3 Years","To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions",[255,256,257,258,27,259,260,261,262],"Cancer of Stomach","Oesophageal Cancer","Gastric Cancer","Gastric Adenocarcinoma","GIST","Neuroendocrine Tumors","Gastric Neoplasm","Esophageal Neoplasms","2025-03-25",{"date":265,"type":35},"2025-03-27",{"date":267,"type":35},"2023-03-14",{"date":269,"type":20},"2028-09-14",{"name":271,"class":42},"Western Sydney Local Health District",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":278,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":132},"100519227","effect-of-geriatric-intervention-in-frail-patients-with-gastric-biliary-and-pancreatic-cancer-receiving-palliative-chemotherapy-100519227","NCT06040801","Effect of Geriatric Intervention in Frail Patients with Gastric, Biliary, and Pancreatic Cancer Receiving Palliative Chemotherapy","Inclusion Criteria:\n\n* Patients aged sixty-five or older with metastatic or unresectable gastric, biliary, and pancreatic cancer.\n* The patient must sign the informed consent form.\n* Estimated survival period of more than 3 months.\n* Conscious and able to communicate verbally or in writing, and willing to cooperate with invasive procedures.\n\nExclusion Criteria:\n\n* Patients with cognitive impairment or unable to cooperate with the interventional procedures as determined by the clinical physician.\n* Patients receiving concurrent other anticancer treatments (radiation or surgery).\n* Patients with multiple types of cancer requiring simultaneous treatment.\n* Patients who have previously participated in this study during a prior chemotherapy regimen.","65 Years",{"count":280,"type":20},138,[23],"Gastric, biliary and pancreatic cancer are commonly malignancies from gastro- intestinal tract in Taiwan. Because lack of specific symptoms at presentation and effective screening methodology, majority of these patients are diagnosed with metastatic or unresectable disease. Palliative chemotherapy is the good standard of therapy for patients with unresectable gastric, biliary and pancreatic cancer with benefit of prolong survival time and improve quality of life.\n\nAlthough the benefit of palliative chemotherapy seems to be the same for elderly and young cancer patients in clinical study, elderly patients are less frequently treated with chemotherapy or treated with suboptimal dosage. Elderly patients do not receive palliative chemotherapy because concerns of elder age, comorbidity, poor performance, lack of social\u002Feconomic support and worry about treatment toxicities.\n\nThe increase in life expectancy of the general population resulted in an increase in the number of elderly patients with cancers referred for palliative chemotherapy. Overtreatment may result in high mortality due to disregard of the aging patients' frailty; on the other hand, under-treatment resulting from over-concern regarding their ability to tolerate treatment, may compromise the survival outcome. Therefore, the appropriately selection of geriatric cancer patients for palliative chemotherapy has to be addressed urgently.\n\nFrailty is a progressive decline of physiological reserve leading to multiple functional disability and increases vulnerability to subsequent morbidity and mortality. Frailty is associated with treatment toxicity, chemotherapy tolerance, and survival outcome in clinical oncology. Recent randomized study reported geriatric intervention significantly improved chemotherapy tolerance in elderly patients. Therefore, the American Cancer Association has recommended routine geriatric assessment and intervention in oncogeriatric patients upon providing antitumor treatments. However, the effect of geriatric intervention on chemotherapy tolerance is seldom in Taiwan.\n\nThis study is an open, randomized, prospective trial to evaluate the effect of geriatric intervention on chemotherapy tolerance in patients with unresectable gastric, biliary, and pancreatic cancer. All patients with receive frailty assessment within 7 days before initiation of first cycle palliative chemotherapy followed by geriatric intervention. The study aim is to compare for chemotherapy tolerance, treatment-related toxicity, and quality of life after completion 3 months chemotherapy treatment course between frail and non-frail patients. This study also aims to explore the effect of geriatric intervention of treatment tolerance, treatment-related toxicity, and quality of life in frail patients with gastric, biliary, and pancreatic cancer receiving palliative chemotherapy.",[27],[285,286,287,288],"Frailty","Comprehensive Geriatric Assessment (CGA)","Chemotherapy","Outcome","2025-02-11",{"date":291,"type":35},"2025-02-13",{"date":293,"type":35},"2021-12-01",{"date":295,"type":20},"2026-07-31",{"name":297,"class":42},"Chang Gung Memorial Hospital"]